ライフサイエンスコーパス: angina pectoris

1 acute coronary syndrome (82 MI, 44 unstable angina pectoris).

2 angina pectoris in most patients with stable angina pectoris.

3 ients with ischemic heart disease and stable angina pectoris.

4 ect adverse outcomes in patients with stable angina pectoris.

5 symptoms and myocardial perfusion in stable angina pectoris.

6 f the endovascular approach in the relief of angina pectoris.

7 001) for combined CHD death/nonfatal MI plus angina pectoris.

8 MI); 86 cases of fatal CHD; and 124 cases of angina pectoris.

9 rent myocardial infarction (MI) and unstable angina pectoris.

10 tractile reserve in patients with refractory angina pectoris.

11 48 (5.9%) men and 41 (5.2%) women developed angina pectoris.

12 of an age less than the duration of unstable angina pectoris.

13 lesions develop in association with unstable angina pectoris.

14 had confirmed acute myocardial infarction or angina pectoris.

15 combined incident coronary events including angina pectoris.

16 mic necroses in other patients with unstable angina pectoris.

17 uced the clinical manifestations of unstable angina pectoris.

18 ostic significance in patients with unstable angina pectoris.

19 (MI), 20 cases of fatal CHD, and 60 cases of angina pectoris.

20 anginal symptoms in patients with refractory angina pectoris.

21 iated with sympathetic phenotypes, including angina pectoris.

22 an association exists between edentulism and angina pectoris.

23 less, and 673,810 (2.3%) were diagnosed with angina pectoris.

24 1.90) were more likely to be associated with angina pectoris.

25 (MI), 44 cases of fatal CHD, and 68 cases of angina pectoris.

26 ients with myocardial infarction or unstable angina pectoris.

27 new treatment for ischaemia in patients with angina pectoris.

28 enal function, congestive heart failure, and angina pectoris.

29 approved for the treatment of chronic stable angina pectoris.

30 ion, in chronic heart failure, and in stable angina pectoris.

31 linical approach to the treatment of chronic angina pectoris.

32 th either acute coronary syndromes or stable angina pectoris.

33 progression in patients with chronic stable angina pectoris.

34 on long-term outcome in patients with stable angina pectoris.

35 fects for patients with chronic, symptomatic angina pectoris.

36 new therapeutic approach to the treatment of angina pectoris.

37 c options exist for patients with refractory angina pectoris.

38 nsidered to be normal and those with typical angina pectoris.

39 ed between patients with unstable and stable angina pectoris.

40 pital with new-onset chest pain or worsening angina pectoris.

41 pital with new-onset chest pain or worsening angina pectoris.

42 betes; 5%, a prior myocardial infarction; 5% angina pectoris; 2.3%, intermittent claudication; and 7%

43 Angina pectoris affects at least 6.6 million people in t

44 monstrated the efficacy of TMR for relieving angina pectoris, although no study to date has specifica

45 A total of 95 patients with angina pectoris and angiographically documented coronary

46 primarily for treatment of hypertension and angina pectoris and are thought to act as allosteric mod

47 is prospective trial patients with suspected angina pectoris and at least one cardiovascular risk fac

48 ly high in subjects with personal history of angina pectoris and familial aneurysm.

49 Secondary endpoints were angina pectoris and hospitalization for heart failure.

50 ally and significantly activated in unstable angina pectoris and is not affected by severity of CAD o

51 Male patients (n = 328) with stable angina pectoris and ischemia on treadmill testing were r

52 Moderate drinking decreases the risk for angina pectoris and myocardial infarction in apparently

53 infarction, 10 angina pectoris, and 12 both angina pectoris and myocardial infarction) after the dia

54 heart by atherosclerotic lesions, leading to angina pectoris and myocardial infarction, damages the h

55 is coronary heart disease, including stable angina pectoris and the acute coronary syndromes.

56 e the population of patients with refractory angina pectoris and to present the therapeutic options c

57 3 first events (11 myocardial infarction, 10 angina pectoris, and 12 both angina pectoris and myocard

58 n trials of hypertension, diabetes mellitus, angina pectoris, and atrial fibrillation provides even m

59 ovascular disorders, including hypertension, angina pectoris, and cardiac arrhythmia.

60 , myocardial infarction, functional class of angina pectoris, and hospitalizations for unstable angin

61 uelae: nonfatal acute myocardial infarction, angina pectoris, and ischemic heart failure.

62 d MI, coronary revascularization procedures, angina pectoris, and sudden CHD deaths.

63 jority of patients (94%) had class III or IV angina pectoris, and two patients (6%) had unstable symp

64 enting with stable angina pectoris, unstable angina pectoris,and ST-segment elevation myocardial infa

65 t disease (CHD); myocardial infarction (MI); angina pectoris; and performance of coronary bypass or a

66 with preserved ejection fraction (HFpEF) and angina pectoris (AP).

67 Although angina pectoris appears to be related statistically to s

68 After we excluded isolated angina pectoris as an initial event, the lifetime risk o

69 Cardiac amyloidosis can present as angina pectoris associated with coronary flow reserve ab

70 time-dependent proportional hazards methods; angina pectoris at 5 years was modeled using univariate

71 dictor of nonfatal myocardial infarction and angina pectoris at 5 years, even after consideration of

72 The use of nitroglycerin in the treatment of angina pectoris began not long after its original synthe

73 l results in 60-90% of diseases that include angina pectoris, bronchial asthma, herpes simplex, and d

74 Non-cardiac chest pain mimics angina pectoris but generally originates from the oesoph

75 alcium antagonists are widely prescribed for angina pectoris but their effect on clinical outcome is

76 ambulatory ischemia in patients with stable angina pectoris, but it remains to be established whethe

77 cardiovascular event (myocardial infarction, angina pectoris, cerebrovascular accidents, or major cor

78 ed as new episodes of myocardial infarction, angina pectoris, congestive heart failure, or stroke.

79 l infarction, CHD death, angiogram-confirmed angina pectoris, coronary artery bypass graft surgery, s

80 he lifetime risks of coronary heart disease (angina pectoris, coronary insufficiency, myocardial infa

81 nce than medical therapy for men with stable angina pectoris due to single-vessel disease.

82 Twenty developed angina pectoris during pacing, while 21 did not.

83 Angina pectoris during RCA occlusion tended to occur in

84 intracoronary ECG ST-segment elevation, and angina pectoris during the same 1-minute coronary occlus

85 tory and duration of clinical improvement in angina pectoris following TMR.

86 exercise tolerance test, and stable chronic angina pectoris (for at least 2 months) were recruited i

87 In patients with suspected stable angina pectoris, global longitudinal peak systolic strai

88 Patients with MI and unstable angina pectoris had higher VEGF levels compared with sta

89 New York Heart Association class or comorbid angina pectoris, had lower activity levels, lived in Eas

90 Postprandial angina pectoris has been recognized for more than two ce

91 nifedipine GITS to conventional treatment of angina pectoris has no effect on major cardiovascular ev

92 d aortocoronary vein grafts and uncontrolled angina pectoris have limited options for therapy.

93 onary revascularization, hospitalization for angina pectoris, hospitalization for congestive heart fa

94 ar mortality, myocardial infarction, stroke, angina pectoris, hospitalization for heart failure, ESRD

95 drugs, used extensively in the treatment of angina pectoris, hypertension, and arrhythmia.

96 The indication for PTCA was stable angina pectoris in 69 patients, unstable angina in 22 an

97 The standard liquid meal precipitated angina pectoris in all patients.

98 rength of association between edentulism and angina pectoris in Mexican adults aged 35 years and olde

99 s is responsible for myocardial ischemia and angina pectoris in most patients with stable angina pect

100 The standard liquid meal induced angina pectoris in patients with coronary artery disease

101 maging, TMR improved the functional class of angina pectoris in patients with end stage coronary arte

102 Stable angina pectoris in women has often been considered a "so

103 iovascular events (myocardial infarction and angina pectoris) in 498 women with systemic lupus erythe

104 apid CAD progression in patients with stable angina pectoris is associated with increased C-reactive

105 Refractory angina pectoris is defined, and traditional medical ther

106 inking to the risk for other events, such as angina pectoris, is not known.

107 Of 50 diseases monitored, a single one, angina pectoris, is significantly elevated (3.3x) in ici

108 ified in network meta-analyses of stroke and angina pectoris, limiting the conclusiveness of findings

109 o 1.093] for every 0.26 mmol/L increase) and angina pectoris (multivariate odds ratio, 1.049 [95% con

110 e used to assess risk for a first CHD event (angina pectoris, myocardial infarction, or cardiac death

111 ears, 55 subjects developed coronary events (angina pectoris, myocardial infarction, or coronary deat

112 -up of 7.9 years, 76 subjects developed CEs (angina pectoris, myocardial infarction, or coronary deat

113 infarction (n=5371, 901 deaths), and stable angina pectoris (n=6536, 965 deaths) in 4 age categories

114 ve patients with clinically suspected stable angina pectoris, no previous cardiac history, and normal

115 for the treatment of myocardial ischemia and angina pectoris not amenable to conventional percutaneou

116 for the treatment of myocardial ischemia and angina pectoris not amenable to conventional percutaneou

117 ther self-reported QoL parameters related to angina pectoris, notably in terms of angina frequency an

118 myocardial infarction, but the prevalence of angina pectoris, of smoking, and of chest pain in the at

119 Angina pectoris often results from ischemic episodes tha

120 OR heart failure OR myocardial infarction OR angina pectoris OR acute coronary syndrome OR coronary a

121 in 72 h of presentation with either unstable angina pectoris or acute myocardial infarction.

122 re American region, older age, no history of angina pectoris or asthma, no use of hypoglycemic agent,

123 or revascularization, or with a diagnosis of angina pectoris or CHD defined by angiography.

124 the duration of symptoms in patients who had angina pectoris or myocardial infarctions.

125 in 444 of 1473 patients with either unstable angina pectoris or non-Q-wave myocardial infarction (NQW

126 26.64), and less likely to have a history of angina pectoris (OR 0.58, 95% CI 0.34-0.99) compared wit

127 rial fibrillation, renal dysfunction, stable angina pectoris, or advanced New York Heart Association

128 atients had stable angina pectoris, unstable angina pectoris, or non-ST-elevation myocardial infarcti

129 t CVD, defined as new myocardial infarction, angina pectoris, or stroke, which developed between base

130 We studied 124 chronic stable angina pectoris patients (84 men; mean age, 61+/-10 year

131 is at rest in patients with suspected stable angina pectoris predicts the presence of coronary artery

132 Candidates with angina pectoris, previous myocardial infarction, or cong

133 ring patch-off hours in patients with stable angina pectoris receiving a beta-adrenergic blocking age

134 TMLR performed in patients with refractory angina pectoris reduces ischemic wall motion abnormaliti

135 cident CHD, including myocardial infarction, angina pectoris, revascularization, and coronary death,

136 ve coronary angiography for suspected stable angina pectoris (SAP) (n = 4131) and an independent coho

137 ients referred for angiography due to stable angina pectoris (SAP) or acute coronary syndrome (ACS).

138 elevation AMI and unstable angina, or stable angina pectoris (SAP).

139 t-elevation myocardial infarction and stable angina pectoris , similar patterns were found albeit les

140 without self-reported CHD (heart attack and angina pectoris), stroke, peripheral vascular disease, a

141 ecently, all with significant improvement in angina pectoris that appears both rapid and sustained.

142 linical outcomes in patients with refractory angina pectoris treated with transmyocardial laser revas

143 75 in the best available therapy group) and angina pectoris (two [3%] of 74 in the ruxolitinib group

144 rdial infarction (MI) (n = 205) and unstable angina pectoris (UAP) (n = 185).

145 ocardial infarction (MI) (n =57) or unstable angina pectoris (UAP) (n =60) were consecutively recruit

146 Patients (n=141) with stable angina pectoris undergoing PCI had serial venous blood s

147 Eligible patients had stable angina pectoris, unstable angina pectoris, or non-ST-ele

148 t plaques in patients presenting with stable angina pectoris, unstable angina pectoris,and ST-segment

149 Overall improvement in angina pectoris was sustained at 1 year by at least one

150 Women with angina pectoris were less likely to undergo cardiac cath

151 with the duration of the episode of unstable angina pectoris were observed in 6 of 21 patients who di

152 ) undergoing coronary angiography for stable angina pectoris were studied.

153 oposed catheter-based therapy for refractory angina pectoris when bypass surgery or angioplasty is no

154 MR) is an operative treatment for refractory angina pectoris when bypass surgery or percutaneous tran

155 We observed a patient with unstable angina pectoris who developed foci of ischemic necroses

156 PVI were observed in 10 patients with stable angina pectoris, with well-defined single vessel coronar

157 s validated using CT images of patients with angina pectoris without known valvular disease (n = 95).

158 However, in the group with angina pectoris, women were considerably less likely to